The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A Double-Blind Study to Evaluate the Effects of Omeprazole and an H2 Antagonist in the Treatment of Barrett’s Esophagus.
- collapse Duodenal Ulcer Relapse During Maintenance Treatment With Omeprazole 20 mg, Omeprazole 10 mg, or Ranitidine 150 mg for Twelve Months
- collapse Open treatment with omeprazole 40 mg once daily during 2-8 weeks and a twelve-month follow-up of the relapse rate of duodenal ulcer during maintenance treatment with omeprazole 20 mg once daily. A double blind multicentre placebo controlled study.
- collapse Duodenal ulcer healing and relief of symptoms during treatment with omeprazole 20 or 40 mg once daily for 2-8 weeks (Study I-900a). Prevention of duodenal ulcer relapse during maintenance treatment with omeprazole 10 mg once daily, omeprazole 20 mg once daily, or ranitidine 150 mg for twelve months (Study I-900b)
- collapse Prevention of symptom recurrence during maintenance treatment with omeprazole 10 mg once daily or ranitidine 150 mg b.i.d for twelve months.
- collapse Effects of elimination of gastro-esophageal reflux on omeprazole on parameters of pre-malignant change and de-differentiation (i.e. cell kinetics, and plasminogen activators), on classical histological criteria and further on the extent of Barrett’s epithelium.
- collapse A comparative study of omeprazole and cimetidine on regression of columnar lined epithelium in patients with Barrett’s esophagus.
- collapse A Randomized, Double-Blind, Parallel-group, Placebo-Controlled comparison of omeprazole 20 mg once daily, omeprazole 10 mg, and placebo in adult patients (18 – 80 years of age) with healed endoscopically-diagnosed gastro esophageal reflux disease (GERD) for 1 year or until relapse.
- collapse Recurrence of Stricture – Omeprazole’s Role Evaluated (RESTORE)
- collapse Omeprazole in the maintenance treatment of erosive peptic esophagitis: a double-blind, controlled study. Multicentre study in Australia including 5 centres.
